151P CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with doublet chemotherapy (Nab-PTX & S-1) and apatinib (anti-angiogenic TKI) for the first-line treatment of stage IV gastric cancer (GC)Qian‐Li Xue, Han Liang, B. Wang et al.|Annals of Oncology|2021Cited by 3
[Prognostic value of a predictive model comprising preoperative inflammatory response and nutritional indexes in patients with gastric cancer].Liang Wu, Xin-Nian Wang, Han Liang et al.|PubMed|2023Cited by 2
Neoadjuvant tislelizumab plus chemotherapy among patients with locally advanced cervical cancer: A prospective, single-arm, phase II trialJindong Sheng, Ke Wang, Changxiao Xu et al.|Gynecologic Oncology|2024Cited by 0